Publicerat: 2022-01-18 10:56:34
Redeye endorses ISAB submitting a whitepaper to the FDA in order to establish the DissolvIt lung model as an FDA-recommended standard research method in the US. We see an interesting year ahead and continue to argue that the share is attractive at current share price levels.
Länk till analysen